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To the Editor: 
 
The joint American Thoracic Society (ATS)/European Respiratory Society (ERS) statement “An official 
American Thoracic Society/European Respiratory Society statement: research questions in COPD” by 
Celli et al. [1] is a timely summary of the current evidence and the questions that arise directly from 
where that evidence reaches its limits. Such documents are crucial in framing research strategies for 
researchers and research funders. 
 
Daily breathlessness at rest or on minimal exertion is experienced by many of the 330 million people 
living with chronic obstructive pulmonary disease (COPD) globally. It is a debilitating and 
burdensome symptom, experienced for long periods of time, not just in the last weeks or months of 
life. It occurs despite inhaled treatments prescribed to reduce breathlessness: their failure to fully 
relieve breathlessness may add to patients' despair and, at the very time when more support is 
needed, doctors often turn away. The majority of people with COPD will have a prolonged period of 
life with such severe breathlessness. The ATS/ERS statement signals the need for research into: 1) 
methods of alleviating breathlessness by modifying the underlying disease course; 2) pulmonary 
rehabilitation; and 3) symptom control and advance planning during the terminal stages of the 
disease. While these are important goals and the document flags symptom control as important 
(and laudably notes that pulmonary function tests and imaging are surrogates for assessing 
breathlessness), the statement ignores the pressing need for research that ensures relief of 
breathlessness for the prolonged duration when COPD is already maximally treated; this seems a 
significant omission. 
 
This burden of breathlessness in COPD starts well before the “end of life” for most people [2–4]. 
Palliating chronic refractory breathlessness must be an ongoing focus for research if we are to make 
a difference to the lives of these tens of millions of people now and into the future [5, 6]. Even if a 
treatment were to be found today that could cure or prevent COPD, there is a generation of people 
who experience breathlessness as a daily challenge that deserve the combined intellectual expertise 
of the global research community. 
 
The inclusion of ways to treat chronic refractory breathlessness more effectively in optimally treated 
COPD is a worthy research goal, building on the emerging evidence of the mechanisms and 
management of breathlessness. Managing breathlessness has the potential to improve markedly 
people's function for day-to-day activities, such as self-care, and ensure that they are more 
comfortable, even when the underlying cause(s) of their breathlessness cannot be reversed or 
stabilised. Level 1 efficacy evidence (meta-analyses), which needs to be confirmed by adequately 
powered trials, already identifies an important role for nonpharmacological interventions, oxygen, 
and regular, low-dose morphine in reducing breathlessness in this population [7–12]. A research 
programme also needs to include subsequent effectiveness studies. The recognition that 
breathlessness is truly multidimensional, and that modification of its affective component can bring 
significant clinical benefits even in the absence of measurable pathophysiological changes, also 
opens new avenues for research [13]. 
 
There is an urgently needed research agenda that aims to improve the quality of life for people with 
chronic refractory breathlessness caused by progressive COPD. Routine assessment of 
breathlessness and its impact on the person's quality of life [13], followed by evidence-based 
management of refractory breathlessness, can be seen as a fundamental human right, and is an 
urgent priority for researchers and funders alike [14, 15]. 
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